PENNVAX-GP acîmredzot strâdâ
Apskatît komentârus (0)
04.06.2019
Farmâcijas kompânijas Inovio speciâlistiem izdevies izstrâdât vakcînu, kas pârbaudîjumos, kuros piedalîjâs brîvprâtîgie, uzrâdîja cerîgus rezultâtus. Ir sperts vçl viens nozîmîgs solis, lai palielinâtu imûnâs atbildes ilgumu.
Izstrâdâtâ vakcîna aktivizç organisma imûno atbildi uz patogçnu un aizsargâ no HIV seðus mçneðus. Tas ir, cilvçka organisms spçj pusgadu ne vien atpazît vîrusu, bet arî sekmîgi cînîties ar to, izsargâjoties no saslimðanas ar HIV-infekciju. Iepriekð visi mçìinâjumi radît vakcînu pret HIV beidzâs ar neveiksmi organisma augstâs imûnâs tolerances dçï pret ðo patogçnu.
Turpmâkie pçtîjumi un jaunas metodikas izstrâdne, pamatojoties uz iegûtajiem rezultâtiem, var novest pie ilgtermiòa vakcînas radîðanas.
************************
Source: «HIV Vaccine Candidate Generated Near 100% Immune Responses» | https://www.precisionvaccinations.com/hvtn-098-pennvax-gp-hiv-vaccine-candidate-maintained-durable-and-robust-immune-responses-month-12 |
<... In a small, Phase 1 clinical study HVTN 098 PENNVAX-GP maintained durable and robust immune responses at month 12, which is a full 6 months after the last dose.
Previously PENNVAX-GP was reported by Inovio Pharmaceuticals, Inc. to elicit the highest overall levels of immune response rates ever demonstrated in a human study, by an HIV vaccine.
Inovio's HIV development focus is for both preventive and therapeutic purposes.
PENNVAX-GP consists of a combination of four HIV antigens designed to generate both antibody and T-cell responses and cover multiple global HIV strains. ...>
Atpakaï